AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15638092 — intervention group
Group type: COMPARATOR
Intervention: Regular DCR group (control)
Number of subjects: 130
Study 11374745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype-consistent information
Number of subjects: 288
Study 11374745 — intervention group
Group type: COMPARATOR
Intervention: Stereotype-inconsistent information
Number of subjects: 288
Study 9491951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 210
Study 9491951 — intervention group
Group type: COMPARATOR
Intervention: AV block pacing
Number of subjects: 210
Study 9491951 — intervention group
Group type: COMPARATOR
Intervention: SSS pacing
Number of subjects: 210
Study 7509329 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vincristine, and DTIC) followed by 35 Gy in 20 fractions
Number of subjects: 102
Study 7509329 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) followed by 35 Gy in 20 fractions
Number of subjects: 102
Study 7509329 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABVD followed by 35 Gy in 20 fractions
Number of subjects: 102
Study 7509329 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV (cyclophosphamide, adriamycin, and vincristine) followed by 25 Gy in 10 fractions
Number of subjects: 102
Study 7509329 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (radical)
Number of subjects: 102
Study 7509329 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (palliative)
Number of subjects: 102
Study 7509329 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (control group)
Number of subjects: 102
Study 2898500 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub (Hibiscrub-ICI)
Number of subjects: 375
Study 2898500 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine scrub
Number of subjects: 375
Study 2898500 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 375
Study 31213445 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised risk-based variable-interval screening
Number of subjects: 4460
Study 31213445 — intervention group
Group type: COMPARATOR
Intervention: Annual screening intervals
Number of subjects: 4460
Study 27001007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine concentration in amniotic fluid
Number of subjects: 42
Study 27001007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine concentration in amniotic fluid
Number of subjects: 42
Study 27001007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine concentration in maternal saliva
Number of subjects: 42
Study 27001007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine concentration in maternal saliva
Number of subjects: 42
Study 27001007 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva cotinine concentration
Number of subjects: 42
Study 27001007 — intervention group
Group type: EXPERIMENTAL
Intervention: Time elapsed since last cigarette
Number of subjects: 42
Study 25572008 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (100 mg/m2 weekly) plus carboplatin (C)
Number of subjects: 1038
Study 25572008 — intervention group
Group type: COMPARATOR
Intervention: solvent-based paclitaxel (200 mg/m2 every 3 weeks) plus carboplatin (C)
Number of subjects: 1038
Study 24236807 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy coaching intervention (SCI)
Number of subjects: 65
Study 24236807 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 65
Study 21311897 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release/extended release (CR/XL) pretreatment
Number of subjects: 30
Study 21311897 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine stimulation
Number of subjects: 30
Study 21311897 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL at low concentrations of dobutamine
Number of subjects: 30
Study 21311897 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL at peak stress (40 μg/kg/min of dobutamine)
Number of subjects: 30
Study 19037200 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 0
Study 19037200 — intervention group
Group type: COMPARATOR
Intervention: Control (Met/Met genotype)
Number of subjects: 0
Study 19037200 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil and Val158Met polymorphism
Number of subjects: 0
Study 17011057 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion
Number of subjects: 0
Study 15290425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% isoflurane (ISO group)
Number of subjects: 2
Study 15290425 — intervention group
Group type: COMPARATOR
Intervention: 7% sevoflurane (SEV group)
Number of subjects: 2
Study 11127498 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Easyhaler
Number of subjects: 32
Study 11127498 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Turbuhaler
Number of subjects: 32
Study 10180369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheaper treatment
Number of subjects: 0
Study 10180369 — intervention group
Group type: COMPARATOR
Intervention: More expensive treatment
Number of subjects: 0
Study 8444537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin
Number of subjects: 100
Study 8444537 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 2944158 — intervention group
Group type: EXPERIMENTAL
Intervention: Local irradiation (45 Gy)
Number of subjects: 149
Study 2944158 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 149
Study 29895280 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education (HE)
Number of subjects: 221
Study 29895280 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 221
Study 29895280 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice (BA)
Number of subjects: 221
Study 27529765 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour time in bed (TIB)
Number of subjects: 68
Study 27529765 — intervention group
Group type: COMPARATOR
Intervention: 6-hour TIB with a 2-hour bedtime delay (late bedtime)
Number of subjects: 68
Study 27529765 — intervention group
Group type: COMPARATOR
Intervention: 6-hour TIB with a 2-hour rise time advance (early rise time)
Number of subjects: 68
Study 27529765 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour TIB
Number of subjects: 68
Study 24472633 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease and care management (D&CM) intervention
Number of subjects: 762
Study 24472633 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (Control)
Number of subjects: 762
Study 22388601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist involvement in drug therapy management, including targeted drug counselling before discharge.
Number of subjects: 77
Study 22388601 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care without pharmacist involvement.
Number of subjects: 77
Study 20439832 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 199
Study 20439832 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 199
Study 18714239 — intervention group
Group type: COMPARATOR
Intervention: Serial CE (concurrent exercise)
Number of subjects: 28
Study 18714239 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CE (concurrent exercise)
Number of subjects: 28
Study 16184458 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive physiotherapy (CDP) including lymph drainage, multi layer compression bandage, elevation, remedial exercises and skin care
Number of subjects: 53
Study 16184458 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (SP) including bandage, elevation, head-neck and shoulder exercises and skin care
Number of subjects: 53
Study 12515747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan (Levo)
Number of subjects: 146
Study 12515747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 11269973 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineutrophil cytoplasmic antibodies (ANCAs) in IBD patients
Number of subjects: 75
Study 11269973 — intervention group
Group type: COMPARATOR
Intervention: Control group (functional bowel disease)
Number of subjects: 75
Study 11269973 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA-positive IBD patients
Number of subjects: 75
Study 8936353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (50/200 mg carbidopa/mg levodopa)
Number of subjects: 170
Study 8936353 — intervention group
Group type: COMPARATOR
Intervention: Sinemet STD (25/100 mg)
Number of subjects: 170
Study 1587068 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg alprazolam
Number of subjects: 24
Study 4027151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 10
Study 4027151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31385029 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-loaded wrist flexor training (4 sets of 6-8 repetitions at 80% of 1-RM)
Number of subjects: 18
Study 28299536 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness for RTW scale (Prepared for action - self-evaluative and Prepared for action - behavioral dimensions)
Number of subjects: 217
Study 28299536 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness for RTW scale (Uncertain maintenance dimension)
Number of subjects: 217
Study 28299536 — intervention group
Group type: COMPARATOR
Intervention: Expectation question about length of sick leave
Number of subjects: 217
Study 27113592 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy
Number of subjects: 21
Study 27113592 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy and surgery
Number of subjects: 21
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Insured adults
Number of subjects: 0
Study 25185135 — intervention group
Group type: COMPARATOR
Intervention: Uninsured adults
Number of subjects: 0
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Publicly insured adults
Number of subjects: 0
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Privately insured adults
Number of subjects: 0
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit frequency
Number of subjects: 0
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare insurance
Number of subjects: 0
Study 25185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Poverty index
Number of subjects: 0
Study 22914470 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic laparoscopic hysterectomy
Number of subjects: 100
Study 22914470 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic hysterectomy
Number of subjects: 100
Study 20156500 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy beverage with health claims
Number of subjects: 108
Study 20156500 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy beverage without health claims
Number of subjects: 108
Study 20156500 — intervention group
Group type: COMPARATOR
Intervention: Less-healthy beverage with increased price
Number of subjects: 108
Study 20156500 — intervention group
Group type: COMPARATOR
Intervention: Less-healthy beverage without increased price
Number of subjects: 108
Study 19378514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of remifentanil (RG)
Number of subjects: 60
Study 19378514 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of sufentanil (SG)
Number of subjects: 60
Study 15838691 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 32
Study 11165726 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy in pregnancy (meta-analysis of trials)
Number of subjects: 72
Study 11165726 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy in pregnancy (prospective cohort)
Number of subjects: 72
Study 9491824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ARTS (120 mg)
Number of subjects: 26
Study 9491824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ARTS (100 mg)
Number of subjects: 26
Study 7933735 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 17
Study 7933735 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 17
Study 7933735 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 17
Study 2826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple hepatic arterial embolizations
Number of subjects: 63
Study 2826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial embolization once + monthly chemotherapy with high doses of 5‐fluorouracil
Number of subjects: 63
Study 2826285 — intervention group
Group type: COMPARATOR
Intervention: Monthly chemotherapy with high doses of 5‐fluorouracil
Number of subjects: 63
Study 2024656 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (initial dose 8.11 mmol (325 mg Ca2+) per meal, adjusted to 14.6 mmol (586 mg) Ca2+ per meal)
Number of subjects: 91
Study 2024656 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 91
Study 319141 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (steroids)
Number of subjects: 0
Study 319141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31416212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiose® (500 mg of 2S‐Hesperidin)
Number of subjects: 15
Study 31416212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28328790 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 0
Study 28328790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 28328790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 25602164 — intervention group
Group type: EXPERIMENTAL
Intervention: HMLE capsules
Number of subjects: 50
Study 25602164 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 50
Study 24851570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal (70 g daily, 3 g beta-glucan)
Number of subjects: 24
Study 24851570 — intervention group
Group type: COMPARATOR
Intervention: Rice porridge (control product, 70 g daily)
Number of subjects: 24
Study 20847731 — intervention group
Group type: EXPERIMENTAL
Intervention: Five feedings
Number of subjects: 35
Study 20847731 — intervention group
Group type: COMPARATOR
Intervention: Three feedings
Number of subjects: 35
Study 20847731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cream intake/kg
Number of subjects: 35
Study 20847731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ice cream fullness
Number of subjects: 35
Study 19217691 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm pulsed dye laser (PDL)
Number of subjects: 18
Study 19217691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG laser
Number of subjects: 18
Study 17208269 — intervention group
Group type: EXPERIMENTAL
Intervention: High duty cycle tracking performance
Number of subjects: 0
Study 17208269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low duty cycle tracking performance
Number of subjects: 0
Study 17208269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous apparent motion display
Number of subjects: 0
Study 15860518 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 microg/kg/day s.c. for 4 consecutive days)
Number of subjects: 20
Study 15860518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11930719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Cement
Number of subjects: 75
Study 11930719 — intervention group
Group type: COMPARATOR
Intervention: 3M‐Vitremer
Number of subjects: 75
Study 9337376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (4x10^5 plaque-forming units per dose)
Number of subjects: 2207
Study 9337376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2207
Study 8201908 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 sets of 7-11 repetitions of bicep curls with dumbbells, three times per week for 8 weeks)
Number of subjects: 16
Study 8201908 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 16
Study 8201908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 2954736 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 24
Study 2954736 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (15 mg/day)
Number of subjects: 24
Study 29587697 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported skirt size (SS) ≥ 18 when aged in 20s
Number of subjects: 94124
Study 29587697 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported skirt size (SS) ≥ 18 at questionnaire completion
Number of subjects: 94124
Study 29587697 — intervention group
Group type: EXPERIMENTAL
Intervention: No change in skirt size (SS)
Number of subjects: 94124
Study 29587697 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in skirt size (SS)
Number of subjects: 94124
Study 28339794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg bid)
Number of subjects: 611
Study 28339794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg bid)
Number of subjects: 611
Study 28339794 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (with heparin bridging)
Number of subjects: 611
Study 28339794 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (without heparin bridging)
Number of subjects: 611
Study 26223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped implementation strategy
Number of subjects: 0
Study 26223232 — intervention group
Group type: COMPARATOR
Intervention: Breakthrough strategy (Control)
Number of subjects: 0
Study 23839984 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding with skin-to-skin contact (BF+SSC Group)
Number of subjects: 136
Study 23839984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose with skin-to-skin contact (Sucrose+SSC Group)
Number of subjects: 136
Study 23839984 — intervention group
Group type: COMPARATOR
Intervention: Skin-to-skin contact (SSC Group)
Number of subjects: 136
Study 23839984 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (Sucrose Group)
Number of subjects: 136
Study 21443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation with 40 mg of enoxaparin subcutaneously once daily for 21 days
Number of subjects: 29
Study 21443837 — intervention group
Group type: COMPARATOR
Intervention: No postoperative anticoagulation
Number of subjects: 29
Study 18493597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTi) using sulfadoxine-pyrimethamine (SP)
Number of subjects: 2485
Study 16574171 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Energy Drink (FED)
Number of subjects: 15
Study 16574171 — intervention group
Group type: COMPARATOR
Intervention: Non Functional Energy Drink (NonFED)
Number of subjects: 15
Study 12679453 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue GH therapy (0.35 IU/kg x wk)
Number of subjects: 24
Study 12679453 — intervention group
Group type: COMPARATOR
Intervention: Discontinue GH therapy
Number of subjects: 24
Study 12679453 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue GH therapy
Number of subjects: 24
Study 11726895 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate Vented Electric Left Ventricular Assist System (VE LVAS)
Number of subjects: 280
Study 11726895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not supported with LVAS)
Number of subjects: 280
Study 9144037 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Heart II intervention
Number of subjects: 0
Study 9144037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8181239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 19
Study 8181239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2905372 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 118
Study 2905372 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin and tobramycin
Number of subjects: 118
Study 31597555 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based self-help cognitive behavioural therapy (tel-CBT)
Number of subjects: 13
Study 29044032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels higher than 50 nmol/L
Number of subjects: 159
Study 29044032 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D deficiency (lower than 37.5 nmol/L)
Number of subjects: 159
Study 25781481 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed casein-based formula (eHCF)
Number of subjects: 119
Study 25781481 — intervention group
Group type: COMPARATOR
Intervention: Probiotic supplementation
Number of subjects: 119
Study 23597811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sliced fruit (apples) served in treatment schools
Number of subjects: 0
Study 23597811 — intervention group
Group type: COMPARATOR
Intervention: Whole apples served in control schools
Number of subjects: 0
Study 21678741 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP T vaccine (Pentaxim)
Number of subjects: 212
Study 19702617 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional weight-bearing exercise program
Number of subjects: 191
Study 19702617 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 191
Study 16738507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation with increased tidal volume
Number of subjects: 10
Study 16738507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation with increased respiratory rate
Number of subjects: 10
Study 16738507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation by decreased respiratory rate
Number of subjects: 10